Brief: Caris Data Validates TET2 Clonal Hematopoiesis As A Biomarker For Enhanced Immunotherapy Response
29/10/2025 13:06
Oct 29 (Reuters) - Caris Life Sciences Inc CAI.O: CARIS DATA VALIDATES TET2 CLONAL HEMATOPOIESIS AS A BIOMARKER FOR ENHANCED IMMUNOTHERAPY RESPONSE Source text: ID:nPn1BJZJKa Further company coverage: CAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caris Life Sciences
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Caris Life Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services
Caris Life Sciences Inc expected to post earnings of 1 cent a share - Earnings Preview
Caris Life Sciences Q1 revenue rises on demand for molecular profiling services